A kind of determination method and detection kit of ischemia-modified albumin

Abstract

The invention provides a method for detecting ischemia modified albumin. According to the method, the characteristic that the binding capacity of the ischemic modified albumin and the cobalt is weakened is utilized, free cobalt in a reaction system is detected by using chemical reagents, the change of the content of the free cobalt is expressed through the change of absorbance, the concentration of the ischemia modified albumin is indirectly expressed, and a color developing agent used in the detection is 2,4-dimercaptopyrimidine and is used for detecting the free cobalt in the reaction system. The method has the advantages that the stability of the color developing agent of the 2,4-dimercaptopyrimidine is higher, the analysis sensitivity is higher, the price is lower, the detection resultis reported based on the concentration of the free cobalt, and the problem that the absorbance of an IMA (ischemia modified albumin) detection result is unstable due to the fact that the performanceof instruments or reagents is different and unstable when the absorbance is adopted for report can be solved. The invention further provides a detection kit for the ischemia modified albumin. The detection kit comprises the reagents used in the method.

Description

technical field [0001] The invention relates to a method for detecting ischemia-modified albumin in human serum, in particular to a method and a detection kit for the determination of ischemia-modified albumin. Background technique [0002] Ischemia modified albumin (IMA) is an ideal myocardial ischemia marker discovered in recent years, and has unique advantages in the early diagnosis of acute coronary syndrome. Acute coronary syndromes (ACS) refers to the pathological phenomena of coronary atherosclerotic plaque shedding, platelet aggregation, and thrombosis resulting in coronary stenosis and obstruction, myocardial ischemia and infarction. From a clinical point of view, it covers A group of consecutively progressive conditions, including unstable angina, non-ST-segment elevation myocardial infarction, and ST-segment elevation myocardial infarction, were identified. [0003] Human serum albumin (HSA) is a circulating protein whose amino-terminal sequence is unique to huma...

AI Technical Summary

Problems solved by technology

[0010] (1) The color developer DTT has a low melting point (42-43°C), sublimates at 37°C and 0.67Pa, is easily oxidized by air, has an unpleasant smell, and can be harmful to health due to inhalation, swallowing or skin absorption

[0011] (2) The chromogenic agent DTT has poor stability. DTT has four isomers in structure, including left-handed and racemic structures, 1, 4-SH and 2, 3-SH structures. Different batches of DTT have different structures and properties due to different production processes

Due to the variety of DTT on the market, the reagents themselves have certain differences, resulting in the test results often being unstable due to the manufacturer, reagent type, batch number, etc.

Moreover, the DTT solution has a relatively short refrigerated or frozen storage stability time

[0012] (3) Chromogen DTT analysis sensitivity: DTT is used as free cobalt chromogen, and the slope of the standard curve is not high (compared with DTE), thus indicating that the resolution of using DTT as free cobalt chromogen is obviously not high

[0013] (4) Reagent price: Due to the characteristics of DTT’s spatial structure, when it reacts with different concentrations of free cobalt, the optimum color development concentration is higher. According to the current market price, although the price per gram of DTT is not high, but due to the concentration used in the determination of DTT method Higher, so the price is slightly higher after making up the test solution using DTT to detect IMA (compared with DTE)

Although dithioerythritol DTE can solve the stability problem, its solubility is low, about 15.4g / l at 20°C, and it is easy to crystallize

Images